Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial.

Saved in:
Bibliographic Details
Title: Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial.
Authors: Pollyea DA; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Stevens BM; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Abbott D; Department of Biostatistics and Informatics, Center for Innovative Design and Analysis, University of Colorado, Aurora, CO, USA., Amaya M; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Gutman JA; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Kent A; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., McMahon C; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Schwartz M; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Smith C; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Dell-Martin J; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Sohalski C; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Ellis A; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Haag M; Department of Pathology, University of Colorado, Aurora, CO, USA., Schowinsky J; Department of Pathology, University of Colorado, Aurora, CO, USA., Pan Z; Department of Pathology, University of Colorado, Aurora, CO, USA., Patel SB; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Ransom M; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Gillen A; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Jordan CT; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA., Pietras EM; Division of Hematology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
Source: EClinicalMedicine [EClinicalMedicine] 2025 Oct 10; Vol. 89, pp. 103546. Date of Electronic Publication: 2025 Oct 10 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: The Lancet Country of Publication: England NLM ID: 101733727 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5370 (Electronic) Linking ISSN: 25895370 NLM ISO Abbreviation: EClinicalMedicine Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2589-5370
DOI:10.1016/j.eclinm.2025.103546